Thromboxane A2 up-regulates neutrophil elastase release in Syrian hamsters with trinitrobenzene sulfonic acid-induced colitis

Journal of Pharmacological Sciences

Volumn 98, Issue 4, 2005, Pages 430-438

  Hirota, Yasushi ^a   Suzuki, Mikie ^a   Katsube, Nobuo ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Neutrophil elastase release; Thromboxane A2; Trinitrobenzene sulfonic acid induced colitis; Up regulation

Indexed keywords

LEUKOCYTE ELASTASE; LIPOXYGENASE; NORDIHYDROGUAIARETIC ACID; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; THROMBOXANE RECEPTOR STIMULATING AGENT; TRINITROBENZENESULFONIC ACID; U 44169; U 44619; UNCLASSIFIED DRUG; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; LEUKOTRIENE B4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENZYME INHIBITION; MALE; NONHUMAN; RECEPTOR BINDING; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; GERMFREE ANIMAL; HAMSTER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SECRETION; SYRIAN HAMSTER; UPREGULATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; COLITIS; CRICETINAE; DISEASE MODELS, ANIMAL; LEUKOCYTE ELASTASE; LEUKOTRIENE B4; MALE; MESOCRICETUS; SPECIFIC PATHOGEN-FREE ORGANISMS; THROMBOXANE A2; TRINITROBENZENESULFONIC ACID; UP-REGULATION;

EID: 24744450015     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0050453     Document Type: Article

References (35)

1. Cooke DM. Inflammatory bowel disease: primary health care management of ulcerative colitis and Crohn's disease. Nurse Pract. 1991;16:27-39.
2. Bustos D, Negri G, De Paula JA, Di Carlo M, Yapur V, Facente A, et al. Colonic proteinases: increased activity in patients with ulcerative colitis. Medicina (B Aires). 1998;58:262-264.
3. Gewirtz AT, Liu Y, Sitaraman SV, Madara JL. Intestinal epithelial pathobiology: past, present and future. Best Pract Res Clin Gastroenterol. 2002;16:851-867.
4. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 1996;91:927-934.
5. Havemann K, Gramse M. Physiology and pathophysiology of neutral proteinases of human granulocytes. Adv Exp Med Biol. 1984;167:1-20.
6. Janoff A. Elastase in tissue injury. Ann Rev Med. 1985;36:207-216.
7. Weiss SJ. Tissue destructions by neutrophils. N Engl J Med. 1989;320:365-376.
8. Saitoh O, Sugi K, Matsuse R, Uchida K, Matsumoto H, Nakagawa K, et al. The forms and levels of fecal PMN-elastase in patients with colorectal diseases. Am J Gastroenterol. 1995;90:388-393.
9. Ottonello L, Dapino P, Pastorino G, Vitale E, Dallegri F. The drug 5-aminosalicylic acid rescues alpha 1-proteinase inhibitor from the neutrophil oxidative inactivation. A possible contribution to its therapeutic action in ulcerative colitis. Digestion. 1992;51:140-145.
10. Hirota Y, Suzuki M, Yamaguchi K, Fujita T, Katsube N. Pathophysiological studies of trinitrobenzene sulfonic acidinduced colitis in Syrian hamsters. Comp Med. 2005;55:45-54.
11. Hawthorne AB, Boughton-Smith NK, Whittle BJ, Hawkey CJ. Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C. Gut. 1992;33:513-517.
12. Ligumsky M, Karmeli F, Sharon P, Zor U, Cohen F, Rachmilewitz D. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology. 1981;81:444-449.
13. Zifroni A, Treves AJ, Sachar DB, Rachmilewitz D. Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut. 1983;24:659-664.
14. Jewell DP. Corticosteroids for the management of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am. 1989;18:21-34.
15. Carty E, Nickols C, Feakins RM, Rampton DS. Thromboxane synthase immunohistochemistry in inflammatory bowel disease. J Clin Pathol. 2002;55:367-370.
16. Casellas F, Papo M, Guarner F, Antolin M, Segura RM, Armengol JR, et al. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol. 1995;7:221-226.
17. Collins CE, Forbes A, Rampton DS. Anti-platelet therapy in active Crohn's disease: An open trial using Picotamide, a thromboxane antagonist. Gastroenterology. 1995;108:A799.
18. Skandalis N, Rotenberg A, Meuwissen S, de Groot GH, Ouwendijk RJ, Tan TG. Ridogrel for the treatment of mild to moderate ulcerative colitis. Gastroenterology. 1996;110:A1016.
19. Wright J, Schenowitz G, Adler G, Schneider H. Ridogrel for the treatment of mild to moderate ulcerative colitis. A placebocontrolled trial. Gut. 1996;39 Suppl 3:A188.
20. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 1975;72:2994-2998.
21. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000;1483:285-293.
22. Chang J, Skowronek MD, Cherney ML, Lewis AJ. Differential effects of putative lipoxygenase inhibitors on arachidonic acid metabolism in cell-free and intact cell preparations. Inflammation. 1984;8:143-155.
23. Japanese Association for Laboratory Animal Science. Guideline for Animal Experimentation. Exp Anim. 1987;36:285-288.
24. Kishikawa K, Tateishi N, Maruyama T, Seo R, Toda M, Miyamoto T. ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Prostaglandins. 1992;44:261-275.
25. Kawabata K, Hagio T, Matsumoto S, Nakao S, Orita S, Aze Y, et al. Delayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters. Am J Respir Crit Care Med. 2000;161:2013-2018.
26. Yoshimura K, Nakagawa S, Koyama S, Kobayashi T, Homma T. Roles of neutrophil elastase and superoxide anion in leukotriene B4-induced lung injury in rabbit. J Appl Physiol. 1994;76:91-96.
27. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109:1344-1367.
28. Kim HS, Berstad A. Experimental colitis in animal models. Scand J Gastroenterol. 1992;27:529-537.
29. Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada JR. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology. 1990;98:269-277.
30. Takahara H, Nakamura Y, Yamamoto K, Sinohara H. Comparative studies on the serum levels of α-1-antitrypsin and α-macroglobulin in several mammals. Tohoku J Exp Med. 1983;139:265-270.
31. Ogletree ML, Allen GT. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J Pharmacol Exp Ther. 1992;260:789-794.
32. Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther. 1985;234:435-441.
33. Rainger GE, Rowley AF, Nash GB. Adhesion-dependent release of elastase from human neutrophils in a novel, flow-based model: specificity of different chemotactic agents. Blood. 1998;92:4819-4827.
34. Safayhi H, Rall B, Sailer ER, Ammon HP. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther. 1997;281:460-463.
35. Ina K, Kusugami K, Yamaguchi T, Imada A, Hosokawa T, Ohsuga M, et al. Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am J Gastroenterol. 1997;92:1342-1346.